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The difference-in-differences approach tested for 
changes in rates of growth between the interven-
tion group and the control group, thereby adjust-
ing for any minor differences in baseline costs. 
In addition, the analysis of covariance was ad-
justed for differences in beneficiary characteris-
tics — including age, sex, race, Hierarchical Con-
dition Category severity score, presence of heart 
failure or diabetes, and baseline costs — at the 
start of each pilot program. In the analysis of 
covariance, the statistically nonsignificant differ-
ence-in-differences effect on the growth in costs 
for Aetna was more than halved, not increased, 
implying that Aetna benefited from a healthier 
intervention population.
Average Medicare monthly care-management 
fees ranged from 5 to 11% of average payments 
per beneficiary per month. Hence, the concern 
over statistical power was unfounded, since we 
would have found savings rates of only 3 to 4% 
that were significant at the 95% confidence lev-
el, far less than paid fees. We observed improved 
performance with the refresh population for sev-
eral companies; however, savings remained sta-
tistically nonsignificant and were less than re-
quired savings. Our results were consistent across 
all eight companies and for both the original 
and refresh populations.
Savings and health outcomes for beneficiaries 
with very short lengths of eligibility were sub-
stantially down-weighted by their fraction of 
eligible time during the intervention, thereby 
avoiding any bias from short spells. Substantial 
regression to the mean (≥50%) over short periods 
increases the estimated variance, thereby reduc-
ing statistical power. Even so, we still found a 
cost savings of 3 to 4%. We directly adjusted for 
regression to the mean by including baseline 
costs in our models.
Terry and Moisuk affirm what we believe to 
be major challenges with improving health out-
comes in the commercial fee-for-service popula-
tion in contrast to a managed-care environment 
in which payers play a role in patients’ access to 
care. Our evaluation of care management for 
high-cost beneficiaries at Massachusetts General 
Hospital showed a statistically significant return 
on investment of 3:1, given a similar intention-
to-treat study design and a substantially smaller 
sample size.1 Case managers became integral 
members of each beneficiary’s primary care team 
with access to real-time clinical information and 
face-to-face interactions with primary care phy-
sicians and beneficiaries. It may be that both 
elements are necessary in the fee-for-service 
population.
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The Human Plasma Lipidome
To the Editor: In their review, Quehenberger 
and Dennis (Nov. 10 issue)1 describe plasma lip-
ids implicated in Gaucher’s disease. Although 
they could not possibly mention every lipid, we 
believe it is worth commenting on the cationic 
amphiphilic glycolipid globotriaosylsphingosine 
(lyso-Gb3) and its contribution to a better under-
standing of the pathogenesis and monitoring 
of Fabry’s disease. High plasma concentrations of 
lyso-Gb3 were observed in patients with this dis-
ease,2 and these levels correlated with several of 
its manifestations3 and decreased in response to 
enzyme-replacement therapy.4,5 Furthermore, lyso-
Gb3 promoted vascular smooth-muscle cell pro-
liferation2 as well as transforming growth 
factor-β1–mediated synthesis of extracellular 
matrix components in cultured podocytes at con-
centrations found in the plasma.6 In Fabry’s dis-
ease, vascular smooth-muscle cells and podo-
cytes are cell targets, whereas fibrosis is a key 
feature of organ injury. The novelty, from a 
pathogenetic point of view, resides in the fact 
that a soluble mediator promotes cell injury in a 
disease long thought to be the result of intracel-
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lular lipid accumulation within lysosomes. This 
paradigm shift may have therapeutic implications.
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The Authors Reply: Although we made every 
effort to be as broad as possible in our article on 
the plasma lipidome in health and disease, space 
restrictions limited the number of lipid biomark-
ers that we could adequately discuss in the con-
text of their potential use as diagnostic tools. As 
the most prevalent metabolic storage disorder, 
Gaucher’s disease was cited as a representative 
example of the numerous lipid-storage diseases, 
including Fabry’s disease.
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Case 32-2011: A Man with Recurrent Pancreatitis
To the Editor: We question the indication for 
endoscopic retrograde cholangiopancreatography 
(ERCP) with sphincterotomy in the teenager de-
scribed in Case 32-2011 (Oct. 20 issue).1 First, 
acceptable explanations for his recurrent epi-
sodes of pancreatitis were discovered (i.e., genetic 
predisposition triggered by alcohol consumption). 
Second, there is no objective documentation of 
sphincter of Oddi dysfunction. Most experts usu-
ally perform sphincter of Oddi manometry (SOM) 
to support the diagnosis.2-5 Third, there was no 
biliary tract abnormality or sphincter stenosis 
present. Biliary sphincterotomy is beneficial in 
patients with SOM-proven sphincter of Oddi 
dysfunction, pancreaticobiliary maljunction, or 
both.4 Fourth, it is completely unclear what type 
of sphincterotomy was performed: biliary or 
pancreatic?3 In addition, where was the stent 
placed? Was it inserted into the common bile 
duct or the pancreatic duct? Was it used to treat 
stenosis of the biliary sphincter or to guarantee 
the flow of pancreatic fluid? In summary, per-
forming a risky procedure (ERCP) in patients with 
a questionable diagnosis of sphincter of Oddi 
dysfunction may not result in any benefit and can 
result in catastrophic pancreatitis. Thus, we want 
to caution other endoscopists against this prac-
tice in similar cases.
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